Benzene Exposure

In July 2025, the U.S. District Court for the Eastern District of North Carolina denied Exxon Mobil's motion to dismiss in Dickerson v. CRC Industries, Inc., et al., allowing myelodysplastic syndrome (MDS) claims to proceed. The court held that disease claims accrue at diagnosis, not exposure cessation, and that North Carolina's repose statutes do not apply to latent occupational diseases absent express legislative inclusion. Separately, the Ninth Circuit in Bowen v. Energizer Holdings, Inc., 2024 WL 4352496 (9th Cir. Oct. 1, 2024), reversed dismissal of consumer benzene-in-sunscreen claims, finding Article III standing allegations were intertwined with merits and required factual development. No MDL consolidation is currently active for benzene exposure.

Consumer sunscreen cases proceed in MDL 2994 (S.D. Fla.) with bellwether trials scheduled for late 2026. Industrial exposure cases continue in state and federal courts, including a July 2025 ruling in Dickerson v. CRC Industries, Inc., E.D.N.C., denying Exxon Mobil's motion to dismiss on statute of repose grounds for MDS claims. The Ninth Circuit affirmed Article III standing in Bowen v. Energizer Holdings, 118 F.4th 1134 (9th Cir. Oct. 1, 2024), allowing sunscreen false advertising claims to proceed.

IARC reclassified automotive gasoline as Group 1 human carcinogen March 2025, strengthening causation arguments. OSHA PEL: 1 ppm (8-hour TWA), 5 ppm (15-minute STEL). NIOSH recommends protection at 0.1 ppm. Over 70 consumer product recalls 2021-2024 including sunscreens, deodorants, antiperspirants. Disease latency 5-40 years for AML/MDS.

• Philadelphia, Pennsylvania

  $725.5 million jury verdict awarded May 2024 to former mechanic with AML linked to benzene exposure; ExxonMobil liable for failure to warn. Philadelphia Court of Common Pleas upheld verdict September 2024, increasing total damages to $816 million. Two-year SOL from diagnosis under Pennsylvania law. Source: Reuters, May 10, 2024.

• North Carolina

  Dickerson v. CRC Industries, Inc., et al., E.D.N.C.: Court denied Exxon Mobil motion to dismiss July 2025, allowing MDS claims to proceed despite repose statute challenge. Plaintiff exposed 1970s-2006 at Weyerhaeuser facility using benzene-containing solvents. Ruling preserves disease-based claims under North Carolina's three-year discovery rule. Source: E.D.N.C. docket, July 2025 order.

• Nevada

  Nevada Supreme Court affirmed $7.5 million verdict December 2014 for former gasoline-tanker truck driver. Precedent for transportation sector benzene exposure claims. Source: Schmidt & Clark case listings.

• Cook County, Illinois

  February 2017 filing by auto mechanic Steven J. Williams alleging myeloma after 35 years occupational exposure. Illinois jurisdiction favorable for latency-period diseases. Source: Schmidt & Clark case listings.

• California

  Stone fabricator silicosis litigation (Contreras Lopez v. artificial stone manufacturers, filed March 26, 2025, L.A. Superior Court) indicates ongoing toxic tort activity; benzene co-exposure in manufacturing settings. Source: Schmidt & Clark filing alert.

• National Consumer Product Exposure

  Valisure independent screening 2021: benzene detected in 192 of 661 sunscreen/after-sun products (29%), with 78 products exceeding FDA 2 ppm limit. Chemical spray formulations highest risk. FDA citizen petition filed May 24, 2021. Source: Environmental Health Perspectives, Vol. 130, No. 3 (2022).

• New York State

  2021 study: 80% of 50 marketed sunscreen products contained benzene; 44% exceeded cancer risk thresholds. Dermal exposure assessment shows significant non-occupational exposure pathway. Source: Pal et al., PMC10330564 (2023).

FDA 2 ppm guidance for unavoidable benzene in drugs distinguishes sunscreen as elective cosmetic use—supports failure-to-warn theories. IARC March 2025 reclassification of automotive gasoline as Group 1 carcinogen strengthens causation evidence. No nationwide tolling agreement identified.